Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread ...

The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.

Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread to other organs – metastasize –. But the causes of this association are ...

Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...

Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread to other organs – ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...

Hemophilia A and B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ... to monitor and achieve antithrombin activity in the target range to reduce ...